Miejsce lisinoprilu we współczesnej terapii pacjentów z nadciśnieniem tętniczym Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2015
Słowa kluczowe:
lisinopril, nadciśnienie tętnicze, ryzyko sercowo-naczyniowe
##plugins.themes.bootstrap3.article.main##
Abstrakt
Lisinopril jest przedstawicielem inhibitorów konwertazy angiotensyny – jednej z głównych grup leków hipotensyjnych o prawdopodobnie najkorzystniejszym, udowodnionym wpływie na poprawę rokowania w wielu grupach pacjentów, w tym wśród chorych wysokiego ryzyka sercowo-naczyniowego oraz chorych z cukrzycą. Stosowanie lisinoprilu zarówno w monoterapii, jak i w postaci preparatów złożonych wiąże się z istotną redukcją wartości ciśnienia tętniczego, a ponadto z dodatkowym, korzystnym działaniem pozahipotensyjnym. Poniższe opracowanie stanowi próbę opisania miejsca lisinoprilu we współczesnej praktyce hipertensjologicznej.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Szymański , F. M. (2015). Miejsce lisinoprilu we współczesnej terapii pacjentów z nadciśnieniem tętniczym. Kardiologia W Praktyce, 9(3), 17-22. Pobrano z https://www.journalsmededu.pl/index.php/kwp/article/view/1334
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Arterial Hypertension 2015; 19: 53-58.
2. Cheng J., Zhang W., Zhang X. et al.: Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern. Med. 2014; 174: 773-785.
3. Savarese G., Costanzo P., Cleland J.G. et al.: A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J. Am. Coll. Cardiol. 2013; 61: 131-142.
4. Matchar D.B., McCrory D.C., Orlando L.A. et al.: Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann. Intern. Med. 2008; 148: 16-29.
5. Chodoff L.: Lisinopril: a new ACE inhibitor for the treatment of hypertension and congestive heart failure. Mt Sinai J. Med. 1990; 57: 169-171.
6. Stone C.K., Uretsky B.F., Linnemeier T.J. et al.: Hemodynamic effects of lisinopril after long-term administration in congestive heart failure. Am. J. Cardiol. 1989; 63: 67-570.
7. Uretsky B.F., Shaver J.A., Liang C.S. et al.: Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses. Am. Heart J. 1988; 116: 480-488.
8. Langtry H.D., Markham A.: Lisinopril: a review of its pharmacology and clinical efficacy in elderly patients. Drugs Aging. 1997; 10: 131-166.
9. Hansson L., Lindholm L.H., Ekbom T. et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756.
10. Goa K.L., Haria M., Wilde M.I.: Lisinopril: a review of its pharmacology and use in the management of complications of diabetes mellitus. Drugs 1997; 53: 1081-1105.
11. Hasslacher C.: Influence of the ACE inhibitor lisinopril on blood pressure, metabolism, and renal function parameter in hypertensive type II diabetic patients: a postmarketing surveillance study. J. Diabetes Complications 1996; 10: 136-138.
12. Butler R., Morris A.D., Struthers A.D.: Lisinopril improves endothelial function in chronic cigarette smokers. Clin. Sci (Lond). 2001; 101: 53-58.
13. Hasslacher C.: Influence of the ACE inhibitor lisinopril on blood pressure, metabolism, and renal function parameter in hypertensive type II diabetic patients: a postmarketing surveillance study. J. Diabetes Complications 1996; 10: 136-138.
14. Black H.R., Davis B., Barzilay J. et al.: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008; 3: 353-360.
15. Glezer M.G., Vygodin V.A., Avakian A.A., Prokof’eva E.B.: Results of the Russian EKSPERT program: post-marketing supervision over efficacy and influence of the preparation Ekvator on quality of life at out-patients with arterial hypertension. Kardiologia 2014; 54: 15-22.
16. Mancia G., Grassi G.: Antihypertensive effects of combined lisinopril and hydrochlorothiazide in elderly patients with systodiastolic or systolic hypertension: results of a multicenter trial. J. Cardiovasc. Pharmacol. 1997; 30: 548-553.
17. Gerc V., Begović B., Vehabović M. et al.: Fixed combination lisinopril plus hydro-chlorothiazide in the treatment of essential arterial hypertension: an opened, multi-centre, prospective clinical trial. Bosn. J. Basic Med. Sci. 2007; 7: 377-382.
18. Gerc V., Begović B., Vehabović M. et al.: Effects of fixed combination of lisinopril plus hydrochlorothiazide on regression of left ventricular hypertrophy in patients with essential hypertension: an opened, multi-centre, prospective clinical trial. Bosn. J. Basic Med. Sci. 2008; 8: 214-219.
2. Cheng J., Zhang W., Zhang X. et al.: Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern. Med. 2014; 174: 773-785.
3. Savarese G., Costanzo P., Cleland J.G. et al.: A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J. Am. Coll. Cardiol. 2013; 61: 131-142.
4. Matchar D.B., McCrory D.C., Orlando L.A. et al.: Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann. Intern. Med. 2008; 148: 16-29.
5. Chodoff L.: Lisinopril: a new ACE inhibitor for the treatment of hypertension and congestive heart failure. Mt Sinai J. Med. 1990; 57: 169-171.
6. Stone C.K., Uretsky B.F., Linnemeier T.J. et al.: Hemodynamic effects of lisinopril after long-term administration in congestive heart failure. Am. J. Cardiol. 1989; 63: 67-570.
7. Uretsky B.F., Shaver J.A., Liang C.S. et al.: Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses. Am. Heart J. 1988; 116: 480-488.
8. Langtry H.D., Markham A.: Lisinopril: a review of its pharmacology and clinical efficacy in elderly patients. Drugs Aging. 1997; 10: 131-166.
9. Hansson L., Lindholm L.H., Ekbom T. et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756.
10. Goa K.L., Haria M., Wilde M.I.: Lisinopril: a review of its pharmacology and use in the management of complications of diabetes mellitus. Drugs 1997; 53: 1081-1105.
11. Hasslacher C.: Influence of the ACE inhibitor lisinopril on blood pressure, metabolism, and renal function parameter in hypertensive type II diabetic patients: a postmarketing surveillance study. J. Diabetes Complications 1996; 10: 136-138.
12. Butler R., Morris A.D., Struthers A.D.: Lisinopril improves endothelial function in chronic cigarette smokers. Clin. Sci (Lond). 2001; 101: 53-58.
13. Hasslacher C.: Influence of the ACE inhibitor lisinopril on blood pressure, metabolism, and renal function parameter in hypertensive type II diabetic patients: a postmarketing surveillance study. J. Diabetes Complications 1996; 10: 136-138.
14. Black H.R., Davis B., Barzilay J. et al.: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008; 3: 353-360.
15. Glezer M.G., Vygodin V.A., Avakian A.A., Prokof’eva E.B.: Results of the Russian EKSPERT program: post-marketing supervision over efficacy and influence of the preparation Ekvator on quality of life at out-patients with arterial hypertension. Kardiologia 2014; 54: 15-22.
16. Mancia G., Grassi G.: Antihypertensive effects of combined lisinopril and hydrochlorothiazide in elderly patients with systodiastolic or systolic hypertension: results of a multicenter trial. J. Cardiovasc. Pharmacol. 1997; 30: 548-553.
17. Gerc V., Begović B., Vehabović M. et al.: Fixed combination lisinopril plus hydro-chlorothiazide in the treatment of essential arterial hypertension: an opened, multi-centre, prospective clinical trial. Bosn. J. Basic Med. Sci. 2007; 7: 377-382.
18. Gerc V., Begović B., Vehabović M. et al.: Effects of fixed combination of lisinopril plus hydrochlorothiazide on regression of left ventricular hypertrophy in patients with essential hypertension: an opened, multi-centre, prospective clinical trial. Bosn. J. Basic Med. Sci. 2008; 8: 214-219.